



Published in final edited form as:

*J Can Res Updates*. 2013 October 31; 2(4): 265–282. doi:10.6000/1929-2279.2013.02.04.5.

## Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma

Janet Wangari-Talbot and Elizabeth Hopper-Borge\*

Fox Chase Cancer Center, Developmental Therapeutics Program, 333 Cottman Ave,  
Philadelphia, PA, USA

### Abstract

Lung cancer is the most commonly diagnosed cancer in the world. “Driver” and “passenger” mutations identified in lung cancer indicate that genetics play a major role in the development of the disease, progression, metastasis and response to therapy. Survival rates for lung cancer treatment have remained stagnant at ~15% over the past 40 years in patients with disseminated disease despite advances in surgical techniques, radiotherapy and chemotherapy. Resistance to therapy; either intrinsic or acquired has been a major hindrance to treatment leading to great interest in studies seeking to understand and overcome resistance. Genetic information gained from molecular analyses has been critical in identifying druggable targets and tumor profiles that may be predictors of therapeutic response and mediators of resistance. Mutated or overexpressed epidermal growth factor receptor (EGFR) and translocations in the echinoderm microtubule-associated protein-like 4 (*EML4*)-anaplastic lymphoma kinase (*ALK*) genes (*EML4-ALK*) are examples of genetic aberrations resulting in targeted therapies for both localized and metastatic disease. Positive clinical responses have been noted in patients harboring these genetic mutations when treated with targeted therapies compared to patients lacking these mutations. Resistance is nonetheless a major factor contributing to the failure of targeted agents and standard cytotoxic agents. In this review, we examine molecular mechanisms that are potential drivers of resistance in non-small cell lung carcinoma, the most frequently diagnosed form of lung cancer. The mechanisms addressed include resistance to molecular targeted therapies as well as conventional chemotherapeutics through the activity of multidrug resistance proteins.

### Keywords

Non-small cell lung cancer; EGFR; EML4-ALK; tyrosine kinase inhibitors; drug resistance; ABC transporters; ABCB1; ABCC1; ABCC10; ABCG2

## INTRODUCTION

Lung cancer is a significant health concern in the United States as it is the leading cause of cancer related deaths. Worldwide, it is also the most commonly diagnosed cancer, the

---

© 2013 Wangari-Talbot and Hopper-Borge; Licensee Lifescience Global.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

\*Address correspondence to this author at the Fox Chase Cancer Center, Developmental Therapeutics Program, 333 Cottman Ave, Philadelphia, PA, USA; Tel: 215-214-1505; Fax: 215-728-3616; Elizabeth.Hopper@fccc.edu.

primary cause of cancer related deaths for men and is surpassed only by breast cancer in women as a cause of cancer related deaths [1, 2]. Tobacco usage has long been the major avoidable behavioral factor linked to lung cancer and is the cause of ~30% of all cancer deaths in developed countries [3]. Voluntary and non-voluntary (second hand smoke) contributes to ~90% of lung cancer cases [4, 5]. Tobacco induced carcinogenesis occurs through various mechanisms including formation of bulky DNA adducts [4], induction of inflammation [6], increased oxidative stress [7] and activation of diverse signaling pathways [6]. Furthermore, environmental and occupational respiratory carcinogens such as asbestos may interact with cigarette smoke and increase the probability of developing lung cancer [8].

Genetic susceptibility also appears to play a role in lung cancer especially in people that develop the disease at 50 years of age or less, compared to people who develop the disease within the median age of onset (66 years) [9]. Familial aggregation of lung cancer has also been reported. Specifically, having a parent or a sibling diagnosed with lung cancer increases the relative risk of developing the disease by 1.5 to 6.1 fold in both smokers and non-smokers, respectively [10, 11]. In addition, several high risk genes that predispose non-smokers to lung cancer have been identified [12, 13]. Studies are required to determine the association between these susceptibility genes and clinical outcomes.

Non-small cell lung cancer (NSCLC) is the most commonly diagnosed form of the disease accounting for over 85% of the cases [14]. NSCLC is a heterogeneous aggregate of histologies with the most common being adenocarcinoma, large cell carcinoma and squamous cell (epidermoid) carcinoma [15, 16]. These histologies have different clinical characteristics but share similar treatment approaches and prognoses. Adenocarcinoma is the most common histology indicated in 35-40% of the cases and most prevalent in non-smokers [15, 17].

The 5 year survival rate of NSCLC varies depending on stage at diagnosis from 52.2% to 25.1% to 3.7% in patients with local, regional or advanced metastatic disease respectively [18, 19]. Approximately, 20-30% of patients present with stage I, II and IIIA disease which is treated with curative intent by surgical resection, chemotherapy and radiotherapy [20, 21]. Stage IA patients have 5 year survival rates of 73% while 5 year survival rates for stage IIIA patients are 24% [20, 22, 23]. Adjuvant cisplatin based therapy increases these survival rates by 5% but disease recurrence is a major issue [24]. However, there is no way to predict patient response as 21% of stage IA and 42% of stage IB disease patients recur and die of the disease while 42% of Stage II patients are cured by surgery and do not require cisplatin adjuvant chemotherapy [20, 22, 25].

Approximately 40-50% of NSCLC patients present with advanced or metastatic stage IIIB and IV disease, are not candidates for curative therapy and are treated with systemic chemotherapy [19, 21]. For patients with unresectable stage III disease, combination platinum-based chemotherapy and radiotherapy is recommended, whereas in stage IV disease, chemotherapy alone is customary [26, 27]. Among these patients, systemic therapy is the only treatment proven to increase survival by up to 8-12 months, decrease symptoms and improve quality of life [28, 29]. The choice of treatment for patients with advanced

disease is dependent on the histological subtype of the disease, molecular tumor characteristics, performance status, comorbidities and prior therapy [29, 30]. In metastatic disease, treatment is based on the combination of cisplatin or carboplatin with drugs such as paclitaxel, docetaxel, gemcitabine and vinorelbine which exhibit superior efficacy compared to single agent platinum therapy [28, 29]. Toxicity appears to be the only major difference between the various platinum-based doublet regimens as they offer similar clinical benefits [31].

Molecular targeted therapies are now included in the treatment regimen of NSCLC since they have been shown to extend progression free survival and improve overall survival [32-34]. The presence of molecular biomarkers such as mutations or amplification of epidermal growth factor receptor (EGFR) [34, 35], echinoderm microtubule-associated protein-like 4-naplastic lymphoma kinase (EML4-ALK) kinase translocation [36], mutations in KRAS [37] and PI3KCA [38] can serve as targets for these therapies but also as indicators of treatment outcomes.

Similar to conventional chemotherapies, these newer targeted agents also have a propensity to fail due to the development of resistance. Drug resistance which can be either pre-existent (intrinsic) or acquired after drug exposure is a major cause of failure in the treatment of malignant disease and remains an unsolved pharmacological problem [39, 40]. Chemoresistance is regulated by complex mechanisms which through multiple cell adaptations, render drugs ineffective in cell killing [41]. Although research has identified some of the adaptations, how to reverse this issue in NSCLC is still enigmatic. As a result, there have been numerous attempts to overcome drug resistance in order to improve the efficacy of chemotherapy and understanding these mechanisms will be critical in solving the resistance issue. In this review, we examine mechanisms through which NSCLC becomes resistant to both targeted therapies and conventional chemotherapeutic agents.

## RESISTANCE TO TARGETED AGENTS IN NSCLC

### Epidermal Growth Factor Receptor (EGFR)

Epidermal growth factor receptor (EGFR, HER-1, ERBB1) is a member of the epidermal growth factor receptor tyrosine kinase family which consists of 3 additional receptors with similar structure: EGFR2/HER-2-NEU/ERBB2, EGFR3/HER-3/ERBB3 and HER4/ERBB4 [42, 43]. These receptors are expressed primarily on the surface of epithelial cells and contain an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain that mediates signal transduction [44, 45]. Upon receptor binding, the receptors form homo or heterodimers, the receptor-ligand complex gets internalized and auto-phosphorylation on tyrosine residues occurs resulting in activation of downstream signaling cascades [46]. Erbb receptors have roles in normal development as Egrf knockout mice die *in utero* and exhibit gross abnormalities of the brain, heart, bone and other epithelial organs [47, 48]. These receptors are implicated in the development and progression of cancer due to their ability to modulate cell cycle progression, apoptosis, cell migration, angiogenesis, migration and drug resistance [49].

Research has shown that EGFR plays an important role in the growth, survival and chemoresistance in NSCLC either by aberrant expression or mutation. Overexpressed EGFR has been reported in 40-80% of NSCLC [45, 50]. Overexpression can occur as a result of various mechanisms including an increase in gene copy number, epigenetic modifications and activation by oncogenic viruses [51, 52]. Somatic activating mutations in the EGFR tyrosine kinase domain (exon 18-21) and deletions of exon 19 have been identified in 10-15% of Caucasian patients and 30-40% of Asian patients [53]. The overexpression or constitutive mutation of EGFR leads to the activation of various signal cascades including the phosphatidylinositol 3-kinase/AKT pathway (PI3K/AKT), the mitogen activated protein kinase pathway (MAPK) and the signal transducers and activators of transcription (STAT) pathway [54, 55]. EGFR overexpression correlates with disease progression, decreased survival, lymph node metastasis and poor chemo-sensitivity [56, 57].

In the past two decades, a variety of tyrosine kinase inhibitors (TKIs) targeting EGFR have been tested in clinical trials. First generation TKIs such as erlotinib and gefitinib inhibit EGFR tyrosine phosphorylation through competitive, reversible binding to the ATP site on the kinase domain [34, 58]. In large randomized studies, erlotinib as a second or third line therapy was shown to confer a survival advantage [59] while gefitinib did not demonstrate a survival advantage except in select clinical subgroups of Asians and never-smokers [60]. Monoclonal anti-EGFR antibodies such as cetuximab, directed to the extracellular domain of the receptor also have reported clinical benefit [56, 61]. In randomized studies comparing the addition of cetuximab to first line chemotherapy, patients with high EGFR expression demonstrated increased overall survival with no meaningful side effects [56, 61].

Among patients with EGFR activating mutations, 70% respond to TKI treatment, while the remaining 30% show intrinsic resistance to these inhibitors [62, 63]. Among patients with intrinsic resistance, presence of drug resistant mutations and modifications in EGFR signaling are well studied mechanisms [63]. The missense mutation in exon 21 (L858R) and the in-frame deletion in exon 19 are more sensitive to TKIs than the exon 20 (T790M) mutation [54]. Interestingly, T790M germ line mutations have been identified in a European family with genetic susceptibility to bronchioalveolar carcinoma, implicating EGFR signaling in lung cancer susceptibility [64]. In sporadic lung cancer with no exposure to tyrosine kinase inhibitors, the mutation has been detected, albeit at very low frequency [65]. In NSCLC cells and tumors treated with tyrosine kinase inhibitors, this mutation has been shown to be one of the major determinants and causes of drug resistance [65, 66].

### Increased PI3K/AKT Signaling

Intrinsic resistance to EGFR inhibitors is associated with increased signaling through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway as a consequence of *PTEN* loss [67, 68]. In erlotinib resistant H1650 lung cancer cells, genomic loss of *PTEN* was accompanied by high levels of phosphorylated AKT [67]. Rescue of *PTEN* loss through expression of exogenous *PTEN* resensitized the cells to erlotinib. In addition, analysis of tumor biopsy samples showed enrichment of EGFR mutant samples with hemizygous loss of chromosome 10 on which *PTEN* is located [67]. The loss of *PTEN* may induce resistance in patients with EGFR mutations possibly by relieving the tumor's dependence on EGFR signaling [67, 69].

Mutations in the PI3KCA and P110 $\alpha$  subunits of PI3K can also induce primary resistance to EGFR TKIs through constitutive AKT activation [70].

### **Insulin-Like Growth Factor Receptor 1 (IGFR-1) Crosstalk**

Crosstalk of EGFR with the Insulin like Growth Factor Receptor 1 (IGFR-1) can also induce intrinsic resistance to EGFR targeted therapies. In a study of surgically resected patients, high co-expression of EGFR with IGFR-1 was reported to have a poor prognosis and was associated with decreased survival [71]. The activation of IGFR-1 by binding of IGF-I and IGF-II to its extracellular domain results in the activation of both MAPK and PI3K/AKT pathways. It is through the activation of PI3/AKT pathway that IGFR-1 can promote resistance to EGFR targeted therapies [72]. An enriched pool of pre-TKI resistant cells that depend on IGFR-1 signaling have been discovered in a heterogeneous pool of cancer cells and only an IGFR-1 inhibitor could prevent the emergence and expansion of EGFR TKI resistant cells [73].

### **KRAS Mutations**

Mutations of the *KRAS* proto-oncogene appear to have a negative effect on NSCLC treated with EGFR TKIs [74-76]. These mutations have been observed in 15-25% of lung cancer samples and in particular, 30-50% of adenocarcinomas [74, 77]. These mutations are found mutually exclusive to EGFR activating mutations as *KRAS* is a downstream effector of the receptor, making these tumors unresponsive to upstream EGFR inhibition therapy [78]. The most commonly observed mutations in *KRAS* are point mutations on codons 12, 13 and 61 which appear to be an early irreversible event in lung tumorigenesis [79, 80]. *KRAS* possesses intrinsic GTPase activity which when constitutively activated by mutations can result in cell transformation and unregulated growth [79, 81]. *KRAS* mutations may also be linked to smoking as they are more common in smokers while EGFR mutations are commonly observed in never smokers [74, 82, 83]. However, *KRAS* mutations have also been found in cases of never smoker patients indicating that despite the strong correlation between smoking and these mutations, predicting *KRAS* mutation status should not depend primarily on a patient's smoking history [37].

Early studies on the role of *KRAS* mutations on EGFR targeted therapy yielded conflicting information. Some studies showed that in resected NSCLC, *KRAS* was a negative prognostic factor while others showed no value of *KRAS* mutations in prognosis [77, 84, 85]. A meta analysis performed by Mascaux *et al.*, with results from 53 clinical studies pointed to *KRAS* as a negative prognostic factor in adenocarcinomas [86]. In NSCLC patients treated with erlotinib or gefitinib, lack of clinical response was common in patients with *KRAS* mutations [87, 88]. *KRAS* may be used to predict chemotherapy outcomes as mutations decrease the response rates of patients treated with cytotoxic drugs such as docetaxel, paclitaxel and carboplatin [76, 89]. In the clinic, the presence of *KRAS* mutations could be used to prevent the administration of chemotherapy to patients who are unlikely to benefit. This information may establish a potential rationale for prospective *KRAS* mutation testing before clinical trial or therapy assignment. Some promising data has also recently emerged showing that the MEK kinase inhibitor selumetinib may benefit *KRAS* mutant patients who have failed prior therapy [90].

## Secondary Mutations in Acquired Resistance

Acquired resistance to EGFR inhibitors is mediated by the development of secondary mutations in the kinase domain of exon 20 at the gatekeeper residue T790M [65, 66]. This gatekeeper residue is a conserved threonine residue located in the hinge region of the kinase domain at the back of the ATP-binding pocket and controls access to a hydrophobic sub-pocket [91]. This mutation has been found in over 50% of patients who were initially responsive to TKI therapy and it is hypothesized that clones in the tumor population carrying this mutation are selected for with TKI therapy [53, 66, 92]. This gatekeeper residue is important as it controls access to the hydrophobic pocket. Mutations change the conformation of the receptor, blocking binding of the TKIs, increasing both the enzymatic activity of the protein and the affinity of mutant proteins for ATP [93-95]. This T790M mutation is analogous to the gatekeeper residue T3151 in BCR-ABL kinase that is associated with acquired resistance to gleevec and imatinib in chronic myelogenous leukemia [96].

Other secondary mutations have been identified but they occur at lower frequency than the T790M mutation [66, 97]. They also confer a lesser degree of resistance than the T790M mutation [98]. These mutations include the T854A located on exon 21 [99], L747S and D761Y both on exon 19 [97, 98]. The T854A mutation was identified in patient samples treated with TKIs but not in their pre-treatment samples [99]. The residue is not conserved in other tyrosine kinases and is located at the bottom of the ATP binding pocket. The mutation causes a conformation change that prevents contact with the TKI. The D761Y mutation is located on the  $\alpha$ -C-helix of EGFR and is similar to a mutation in BCR-ABL, D276G, that is associated with acquired resistance after imatinib treatment [100]. The L747S mutation lies at the start of the  $\beta$ 3 strand and the  $\alpha$ -C-helix [98] and has analogous residues in BCR-ABL (L237M) and ERBB2 (L755S or P) that have been identified in TKI resistant disease [98].

The occurrence of these secondary mutations spurred development of second and third generation irreversible TKIs which bind covalently to the cysteinyl-797 residue in the pocket of the EGFR-kinase domain and overcome resistance driven by the T790M mutation [101]. These agents show greater potency in the inhibition of kinase activity *in vitro* and *in vivo* compared to erlotinib and are in various stages of clinical testing [102, 103]. Dacotinib appears promising in phase I and II clinical trials in NSCLC that has failed TKIs and chemotherapy. It shows benefit in progression free survival and a trend towards increased overall survival [102]. Afatinib, an EGFR and HER2 irreversible inhibitor has been shown to reverse the effects of the T790M mutation in preclinical lung cancer studies [104]. In clinical trials, afatinib did not improve overall survival but showed a modest improvement in progression free survival after failure of erlotinib or gefitinib [105, 106].

Several drawbacks are associated with these irreversible EGFR-TKIs. The covalent attachment of the kinase inhibitors to the kinase pocket does not discriminate against wild type EGFR or the mutant proteins [94]. This may be the primary reason why these drugs modestly inhibit mutant T790M driven cancer signaling and suggests that these TKIs are less effective than previously thought. Recently however, a PEG-ylated anilinoquinazoline

derivative labeled with  $^{18}\text{F}$  fludeoxyglucose ( $^{18}\text{F}$ ) developed for use in positron emission tomography (PET) imaging has shown the ability to discriminate between wild type EGFR, mutant L858R or T790M in the irreversible binding which is of benefit in a clinical setting [107]. Dose limiting toxicities are another significant issue with these irreversible TKIs. Excessive adverse effects such as severe diarrhea result in reduction in drug dosage and interruptions in treatment which lowers the bioavailability of the inhibitors to levels insufficient to suppress EGFR activity [108]. Thus, further studies are required to determine dosing schedules that alleviate the adverse effects in order to achieve clinically effective inhibitor levels.

### Epithelial to Mesenchymal Transition

In cancer cells, epithelial to mesenchymal transition (EMT) a process characterized by the loss of epithelial junction markers such as E-cadherin or  $\gamma$ -catenin and gain of mesenchymal markers such as fibronectin or vimentin is associated with progression, metastasis and drug resistance [109, 110]. In NSCLC cells and tumors, an EMT signature of 76 genes has been identified by Byers *et al.*, through high throughput genomic and proteomic analysis in the quest to understand how this transition affects the disease [111]. It has been reported that EMT decreases sensitivity to conventional chemotherapeutics or inhibitors of EGFR and PI3K *in vitro*, *in vivo* and in patients [110, 112]. Decreased expression of E-cadherin and increased expression of fibronectin or vimentin appears to be a common feature of NSCLC cells and tumors resistant to gefitinib or erlotinib regardless of EGFR status and independent of secondary mutations [113]. Restoration of the epithelial phenotype by E-cadherin expression or inhibition of Axl, Notch and TGF- $\beta$  [114] signaling has been shown to restore drug sensitivity and should be explored as alternate therapeutic strategies in lung cancer.

### MET Amplification

Overexpression of hepatocyte growth factor (HGF) receptor through amplification of the *MET* gene has been observed in both TKI naïve and treated patients [115-117]. Amplified *MET* has been implicated in TKI resistance and has been detected in ~20% of patients exhibiting acquired resistance to EGFR inhibitors [117]. Resistance from *MET* amplification occurs as a result of aberrant activation of PI3K signaling *via* epidermal growth factor receptor 3 (ERBB3) driven mechanisms [115]. Monoclonal MET and HGF antibodies as well as small molecule kinase inhibitors are in various stages of preclinical and clinical trials [117, 118]. Combinatorial therapies with EGFR and *MET* inhibitors may be beneficial in alleviating resistance in lung cancer patients.

### Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase (EML4-ALK)

The *EML4-ALK* fusion gene is formed after the fusion of the echinoderm microtubule-associated protein-like 4 (*EML4*) and anaplastic lymphoma kinase (*ALK*) [36, 119]. *ALK* is a transmembrane protein which is not normally expressed in the lung [36], while *EML4* is a ubiquitously expressed, intracellular localized protein with roles in microtubule assembly [120]. *ALK* has been previously identified in tumors showing chromosomal rearrangements such as anaplastic large cell lymphoma and inflammatory myofibroblastic tumors [121]. In

lymphomas, ALK fuses with nucleophosmin (NPM) forming the NPM-ALK fusion product which drives survival of anaplastic large cell lymphoma [122]. The ALK fusion point appears conserved and results in fusion of the whole extracellular domain of ALK to its fusion partners [36]. This chimeric protein is constitutively active and can activate both MAPK and PI3K/AKT signaling [36]. Over 10 variants of EML4-ALK fusion products arise from different breakpoints on EML4 exons and all appear to have transformative abilities [123].

EML4-ALK appears uncommon in lung cancer and has been detected in about 3-8% of overall NSCLC cases [124, 125]. In never smokers, some studies indicate that the prevalence maybe as high as 20-30% of NSCLC cases [126, 127]. The clinical characteristics associated with EML4-ALK mutations are similar to those of EGFR with the translocation more commonly observed in never smokers with adenocarcinoma histology tumors who tend to be younger with a median age of 52 and have advanced stage disease [125, 127]. The translocation is found mutually exclusive of EGFR and KRAS mutations and predicts a poor response to EGFR TKI therapy [126, 127]. In a study by Shaw *et al.*, patients with *EML4-ALK* translocations treated with erlotinib did not show a clinical response to erlotinib treatment and had lower progression free survival as well as overall survival [127]. In the same study, patients with the translocation treated with standard cytotoxic therapies showed a lower response rate to platinum therapies compared to patients with EGFR mutations though these differences were not statistically significant [127]. These findings are highly similar to those observed in patients with KRAS mutations. Thus it appears that NSCLC with *EML4-ALK* translocation needs to be treated as distinct subgroup with its own pathological and clinical features which would benefit from ALK targeted therapy.

Various ALK inhibitors have been tested pre-clinically and clinically with crizotinib showing the most promise [128]. Crizotinib is an oral ATP competitive tyrosine kinase phosphorylation inhibitor that can inhibit both ALK and MET kinases [129]. A phase I clinical trial of crizotinib reported an impressive response rate of 57% with progression free survival of over 6 months by study reporting time and minimal toxicity [124]. In a follow up phase II trial, crizotinib treatment was associated with increased overall survival in advanced NSCLC when given as a second or a third line agent [130].

### **EML4-ALK Secondary Mutations**

Similar to other tyrosine kinase inhibitors, patients treated with crizotinib eventually develop resistance and mutations that lead to resistance have been reported [131, 132]. In one report, the patient developed two *de novo* mutations within the kinase domain of EML4-ALK, C1156Y and L1196M [131]. The L1196M mutation has been shown to be a “gatekeeper” mutation similar to that observed in NPM-ALK that also renders that fusion protein resistant to ALK inhibition [133]. It also corresponds to the amino acid residues T315 in BCR-ABL and T790 in EGFR which are involved in acquired resistance [133]. The L1196M mutation is hypothesized to induce steric interference of crizotinib binding similar to those in BCR-ABL and EGFR [134, 135]. An *in vitro* model of EML4-ALK with the L1196M mutation showed that the cells were still dependent on ALK mediated signaling for tumor



maintenance but are resistant to ALK inhibition [132, 136]. Several other drugs have shown activity in inhibiting mutations induced by crizotinib and are in various stages of pre-clinical and clinical testing [137].

### **ALK Copy Number Gain and Emergence of ALK - Fusion Negative Tumors**

In addition to the secondary gate keeper mutations, it appears that an increase in *ALK* gene copy numbers can occur after crizotinib treatment resulting in resistance. Several reports have identified 4-5 fold amplification of *EML4-ALK* in NSCLC after crizotinib treatment [136, 138, 139]. These patients with the copy number increases tend to progress on ALK inhibitor therapy and should be considered for different therapies. On the other hand, it has also been reported that some patients who previously tested positive for *EML4-ALK* rearrangements before therapy no longer show evidence of the fusion gene when tested with FISH or RT-PCR analysis [139]. Interestingly, some of these tumors now harbor exon 20/21 EGFR or KRAS G12C/G12V mutations that were absent before ALK inhibitor treatment [138, 139]. These tumors appear to have switched oncogenic drivers as a mechanism of ALK inhibitor resistance and the patients may benefit from EGFR treatment. Conversely, some of these fusion negative tumors do not show any secondary drivers and therefore the mechanism of resistance remains unknown. Understanding the genetic changes associated with crizotinib resistance in these patients will be important in determining what patients would be of benefit.

### **Heat Shock Protein (Hsp90) Targeting in EMK4-ALK Positive Tumors**

A potential mechanism of overcoming EML4-ALK secondary mutation resistance involves the use of inhibitors to the protein folding chaperone, heat shock protein (Hsp90). Hsp90 is abundantly expressed and some of its known substrates are steroid hormone receptors and kinases involved in signal transduction [140]. Hsp90 is considered a “cancer chaperone” and an emerging candidate in cancer therapeutics as some of its well known clients include HER2, mutant KIT, EGFR and BCR-ABL [141]. It is required for the stability of these aberrantly activated/expressed proteins. Hsp90 inhibitors have reported activity against both the native and mutant fusion proteins in NSCLC [132, 142]. The inhibitors rapidly degrade EML4-ALK resulting in downstream signaling pathway inhibition, induction of cell growth arrest and apoptosis [132, 143]. In the clinic, Hsp90 inhibition has produced clinical responses in ALK positive patients who have failed crizotinib therapy [143, 144].

### **Role of Multidrug Resistance Proteins in NSCLC**

Multidrug resistance (MDR) is a well characterized broad pattern of cross resistance to various structurally unrelated drugs after exposure to a single drug observed in *in vitro* culture models and in the clinic. The MDR phenotype can arise as a result of cellular adaptations including reduced drug uptake, increased drug efflux, alterations in intracellular drug distribution and inadequate induction of apoptosis [40, 145]. To date, the mechanism most associated with efflux of cytotoxic compounds involves membrane transport proteins. Membrane proteins belonging to the ATP binding cassette (ABC) transporter super-family have been found to actively expel a wide array of cytotoxic compounds in a process dependent on ATP hydrolysis [146]. The multidrug transporter MDR1 or P-glycoprotein (P-

gp/ABCB1) is the most well characterized of these transmembrane efflux pumps and has been linked to drug resistance in mammalian cell lines and human tumors [147]. Modulation of the transport properties of P-gp has been a popular investigation point with various strategies of overcoming P-gp-mediated resistance proposed, but for the most part, these efforts have been futile [148, 149]. Other ABC transporters such as Multidrug Resistance Protein 1 (MRP1/ABCC1) [150], and Breast Cancer Related Protein (BCRP/ABCG2) [151] have also been investigated for potential roles in chemoresistance due to their drug efflux activities. These transporters have broad substrate specificity which can explain their roles in cross resistance, but these characteristics also makes them ideal candidates for investigation in both intrinsic and acquired resistance in NSCLC. In this section, we examine the roles of ABCB1, ABCC1, ABCG2 and ABCC10 in NSCLC chemoresistance.

### ABCB1/MDR1/Pgp

ATP binding cassette, sub family B, member 1 (ABCB1) also known as multidrug transporter (MDR1) or P-glycoprotein (P-gp) was the first human ABC transporter characterized and implicated in the development of multidrug resistance [152]. It is expressed at low levels in most tissues but it is highly expressed in organs involved with barrier functions or excretion such as the liver, blood-brain barrier, placenta and the intestines [40, 153]. ABCB1 transports hydrophobic substrates, lipids, steroids, antibiotics, antihistamines, anticancer drugs such anthracyclines, *vinca* alkaloids and taxanes [153, 154]. *ABCB1* overexpression has been identified in many forms of cancer and has been conclusively linked to poor treatment outcomes in breast cancer [155], and acute myelogenous leukemia (AML) [156].

In the normal lung, ABCB1 expression has been detected on the apical side of epithelial cells of the trachea and major bronchi [157, 158]. In lung cancer, evidence showing a significant role of *ABCB1* overexpression in chemoresistance has been contradictory. These conflicting results obtained during mRNA analysis by reverse transcription-polymerase chain reaction and protein analysis by immunohistochemistry may be due to several factors [159]. Contamination of tumor samples with normal tissue, poor sensitivity, specificity and quantitation difficulties are culprits for these contradictory findings. To address these issues, uniform analytical criteria need to be established.

Lai *et al.*, reported low messenger RNA (mRNA) expression in analyses of 67 cell lines and 24 tumor samples. Relative higher expression was only observed in tumors with neuroendocrine markers. In the study, no correlation between *ABCB1* expression and *in vitro* cell line chemosensitivity, prior therapy status of the patients or clinical therapy outcomes was reported [160]. Immunohistochemical analysis of ABCB1 in tumor samples showed low heterogeneous expression only in 3-15% of tumor samples with no correlation to prognosis [161, 162]. In a disparate report, Beer *et al.*, surprisingly detected expression in 34.6% of chemotherapy or radiotherapy naïve adenocarcinomas by immunohistochemistry [163]. They also reported more prominent expression on the invasion front of the tumors suggesting a possible of P-gp in enhancing the invasive potential of tumor cells.

Using patient derived xenografts not selected for resistance, Merk *et al.* examined the role of the intrinsic expression of various transporters including *ABCB1* in resistance to drugs such

as etoposide, carboplatin and paclitaxel or targeted agents such as erlotinib [164]. In this report, there was no correlation between the expression of *ABCB1* mRNA and chemosensitivity. These findings contradict those by Choi *et al.*, reporting that indeed, there is a correlation between *ABCB1* expression and paclitaxel response in patients [165]. Other studies have also reported that high expression of *ABCB1* at protein and gene levels results in decreased drug sensitivity *in vitro*, *in vivo* [166] and in the clinic [167]. The contradictory nature of these studies examining *ABCB1* expression and roles in resistance in lung cancer suggest that further investigation is required to substantiate the importance of this transporter in this disease.

*ABCB1* expression in lung cancer may have roles in chemoresistance through interactions with TKIs. It has been reported that *ABCB1* can induce resistance to BCR-ABL and EGFR TKIs by reducing drug uptake [168, 169]. Some TKIs have been shown to activate *ABCB1*'s ATPase activity and are transport substrates at low concentrations [170]. This is supported by observations demonstrating that knockdown of *ABCB1* by small interference RNA (siRNA) increases the intracellular concentrations of TKIs such as imatinib and erlotinib [171, 172]. Other TKIs such as nilotinib do not appear to be strong *ABCB1* substrates as siRNA knockdown does not result in increased accumulation suggesting that there is selectivity in TKI transport by these pumps [173, 174]. Moreover, it has also been reported that some TKIs can upregulate ABC transporters including *ABCB1* [175]. Harmsen *et al.*, have described the upregulation of *ABCB1* by gefitinib, erlotinib, sorafenib and nilotinib after 48 hour treatment with clinically relevant concentrations [175]. *ABCB1* induction in this report was mediated by the nuclear receptor pregnane X. This upregulation affects the accumulation of *ABCB1* substrates *in vitro* suggesting that this may be a factor in drug resistance. Conversely, other studies have shown that TKI's such as gefitinib and erlotinib inhibit the transport functions of *ABCB1* at clinically achievable levels thus reversing resistance to cytotoxic drugs *in vitro* by increased accumulation and decreased efflux [176, 177]. It therefore appears that for therapeutic benefit in the clinic, factors such as transporter expression and usage of non-toxic but clinically relevant doses of the TKI to inhibit the efflux function of the transporter would need to be considered before regimen administration.

### **ABCC1/MRP1**

ATP binding cassette, sub family C, member 1 (*ABCC1*) also known as Multidrug resistance protein 1 (*MRP1*) is an efflux pump originally discovered in doxorubicin resistant lung carcinoma cells displaying a multi-drug resistant phenotype without *ABCB1* expression [150]. *ABCC1* is expressed ubiquitously with particularly higher expression detected at the blood-brain barrier, intestines, choroid plexus and oral mucosa [178, 179]. *ABCC1* expression in the lung is higher than in any other solid organs and thus it may have protective roles against air pollution and inhaled toxins [180, 181]. *ABCC1* transports physiological substrates including leukotriene C<sub>4</sub>, glutathione conjugates, bile acids, folic acid but also confers resistance to drugs such doxorubicin, methotrexate, etoposide and vincristine [182, 183].

*ABCC1* expression in lung tumors has been reported by various groups utilizing different techniques. Using Northern blotting, Ota *et al.* identified *ABCC1* expression in 31.6% of NSCLC, predominantly in squamous cell carcinoma and correlated with poor response to etoposide and vindesine [184]. Sugawara *et al.* demonstrated by immunohistochemistry that *ABCC1* was more abundantly expressed in adenocarcinomas than squamous and large cell carcinomas [185]. Increased *ABCC1* overexpression in lung cancer cells has been linked to increased copy number of chromosome 16 on which the *MRP1* gene is located [186]. A report by Doubre *et al.*, showed 3-fold higher *ABCC1* expression level in NSCLC whose aneuploid cells showed a gain of chromosome 16 in diploid normal and carcinomatous cells [186]. No correlation however has been established between *ABCC1* expression and clinicopathological parameters such as sex, age, smoking history, histology and tumor staging [187]. In the clinic, a strong correlation has been reported between high expression and negative response to cisplatin doublet therapy with vinorelbine, gemcitabine and paclitaxel [187, 188]. In addition, *ABCC1* expression can signify overall poor prognoses in patients, a decrease in progression free survival and overall survival [184, 188]. It thus appears that *ABCC1* may have strong implications for management of NSCLC and not surprisingly design of *ABCC1* specific inhibitors and modulation of *ABCC1* as a therapeutic measure is under active investigation [189, 190].

### **ABCC10/MRP7**

ATP binding cassette, sub family C, member 10 (*ABCC10*) also known as Multidrug resistance protein 1 (*MRP7*) is widely expressed in most tissues at low levels [191-193]. As an efflux pump, *ABCC10* extrudes a wide range of anticancer drug substrates. It transports and confers resistance to taxanes, *vinca* alkaloids, anthracyclines and epothilone B [194, 195]. In a knockout mouse model, *Abcc10* has been confirmed to be a major efflux pump for paclitaxel *in vivo* [196]. Upon exposure to sublethal doses of paclitaxel, these *Abcc10*<sup>-/-</sup> mice exhibited significant damage to lymphoid and hematopoietic tissue.

Up-regulated expression of *ABCC10* has been detected in tumors including pancreatic adenocarcinoma [197], colorectal cancer [198] and NSCLC [199]. In colorectal cancer, an inverse correlation between *ABCC10* expression and clinical tumor grading has been reported [198]. In this disease, tumor aggressiveness is associated with a decrease in transcript levels [198]. In a study by Wang *et al.*, characterizing expression in 155 matched normal and NSCLC surgical specimens, *ABCC10* was localized to the membrane and cytoplasm in normal lung tissue, lung adenocarcinoma and squamous cell carcinoma [199]. Significantly, normal tissue showed little to no *ABCC10* expression, squamous cell carcinoma moderate expression while adenocarcinomas showed the highest expression. Additionally, differences were noted in the pathological staging of the adenocarcinomas with TNM stage III tumors showing significant more expression than stage I and II tumors. This study by Wang *et al.* is important as it offers the first characterization of *ABCC10* expression in a large panel of untreated NSCLC tumor specimens.

In addition to this study, several *in vitro* studies support a role of *ABCC10* in lung cancer. Oguri *et al.* have reported that *ABCC10* may be a predictive biomarker for paclitaxel resistance in lung cancer cell lines [200]. Analysis of the paclitaxel-selected and resistant

subline PC-6/TAX1-1, showed higher expression of *ABCB1* and *ABCC10* when compared to parental PC-6 cells. An inverse correlation was established between the expression of *ABCC10* and sensitivity to paclitaxel *in vitro* in PC-6/TAX1-1 cells and in an additional panel of 17 NSCLC cell lines, 13 of which did not express *ABCB1*. Pretreatment of the NSCLC cells with a non-specific ABCC subfamily inhibitor, sulfapyrazone led to enhanced cytotoxicity of paclitaxel and increased intracellular accumulation of the drug. In a separate study, *ABCC10* has been suggested to be a marker for vinorelbine resistance in NSCLC [201]. Up-regulated expression of *ABCC10* was observed in vinorelbine selected NSCLC cell lines. This upregulation was associated with decreased sensitivity to the drug and was reversed by *ABCC10* siRNA. Given that most of the *in vitro* studies reported on *ABCC10* in lung cancer are from drug selected cell lines, further investigation on non-drug selected backgrounds are required.

### ABCG2/BCRP

ATP binding cassette, sub family G, member 2 (*ABCG2*) also known as Breast cancer related protein is an ABC half transporter originally identified in a MCF7 human breast cancer subline resistant to anthracyclines [151]. In this study, *ABCG2* expression resulted in reduced accumulation of daunorubicin, and increased resistance to anthracyclines and mitoxantrone [151]. *ABCG2* expression also mediates resistance to topoisomerase 1 inhibitors such as SN-38, irinotecan and topotecan [202, 203]. It has however not been shown to confer resistance to paclitaxel, cisplatin or vinka alkaloids [151, 204]. *ABCG2* expression has been identified in the epithelium of small intestines and colon, liver, breast ducts and lobes, in vein and capillary epithelium, blood-brain barrier, blood-testis barrier suggesting roles in tissue protection and regulation of drug uptake from the gut [205, 206].

In the normal lung, *ABCG2* protein expression is low and lesser than *ABCB1* and *ABCC1* with the expression localized to the epithelial cell layer, seromucinous gland and small capillaries [203, 207]. In tumors, strong *ABCG2* expression has been detected in a majority of malignancies with immunoreactivity observed in over 10% of the cells localized in both the membrane and cytoplasm [208]. *ABCG2* expression seems to have the highest prognostic value in leukemia and is commonly linked to therapy failure [206]. In NSCLC, *ABCG2* expression appears to show the greatest clinical correlation with low responses to platinum based agents [209]. *ABCG2* expression and correlation with sensitivity to other standard cytotoxic therapies in NSCLC is not compelling. In a study using patient derived xenografts, expression was not a significant player in the response to paclitaxel, carboplatin, gemcitabine and erlotinib and mRNA expression only correlated with etoposide sensitivity [164].

*ABCG2* expression in NSCLC shows some association with acquired resistance to TKIs and similar to observations in *ABCB1*, low concentrations of TKIs stimulate *ABCG2* ATP hydrolysis, but inhibit transport at higher concentrations [210]. In NSCLC, it has been reported that *ABCG2* expression may be a factor in gefitinib resistance, but it is important to note that gefitinib is both a transport substrate and inhibitor of *ABCG2* [211]. In a case reported by Usuda *et al.*, despite initial response, the disease progressed while on gefitinib and while no secondary EGFR mutations were found, *ABCG2* expression was detected in

the recurrent tumor and was suggested to be the cause of resistance [212]. Studies to elucidate the mechanism of ABCG2 expression and correlation with resistance to EGFR inhibitors found elevated levels of wild type EGFR in the nucleus [213]. This increased expression was associated with increased phosphorylation of AKT at Ser-229. In the nucleus, EGFR targets the *ABCG2* promoter and enhances its expression. These findings illustrate the complex genomic interactions involved in resistance mechanisms. The poor clinical outcome reported indicates that ABCG2 may be a negative predictive factor in patients with wild-type EGFR and that it could be a potential target to increase sensitivity to these inhibitors. On the contrary, there is a positive link between ABCG2 and tyrosine kinase inhibitors as erlotinib, gefitinib and AG1478 have been shown to antagonize ABCG2 transport functions [177, 210, 214]. Similar to ABCB1, how to harness the ABCG2 inhibitory effects of TKIs for resistance reversal requires further investigation.

Active research continues to identify the roles of ABC transporters in NSCLC and lung biology but hurdles exist. Most of the information currently available on the expression of ABC transporters in normal and cancerous lung has been obtained from archival tissue and cell line studies due to lack of lung-tissue specific animal models. Lung-specific engineered mouse models of ABC transporters would be beneficial in answering queries about roles in development given the complex lung architecture, the substrates of these transporters in lung and bronchial tissues as well as roles in lung cancer biology and chemoresistance. One of the other hurdles faced in the effort to develop inhibitors for the ATP transporters has been lack of specificity. For instance, ABCB1 inhibitors such as cepharanthine and tariquidar also reverse ABCC10 mediated resistance [215, 216]. Additionally, tyrosine kinase inhibitors such as lapatinib, nilotinib and erlotinib are reversal agents for ABCC10 resistance but they also inhibit the activity of ABCB1 and ABCG2 *in vitro* [217, 218]. However, questions about this off-target activity of TKIs against ABC transporters and how it relates to tyrosine kinase receptors exist and need to be resolved. Furthermore given the ABC transporter targeting activity of these TKIs, they could serve as backbones for the design of novel ABC transporter inhibitors. With the emerging roles of ABC transporters in NSCLC, it is to be expected that in the future, understanding how to successfully target the efflux functions of these proteins may provide another strategy to increase the survival and promote positive treatment outcomes of NSCLC patients.

## CONCLUSION

In this review, we have covered some of the causes of intrinsic and acquired resistance in NSCLC. The available genetic information correlating to positive or negative clinical parameters expands the field of pharmacogenetic driven therapies. Given that this disease is highly refractory to therapy, understanding how to tailor systemic or targeted therapy to patients sharing a common genetic marker can significantly improve benefit. Pharmacogenetic testing is already incorporated in some clinical settings during clinical trials or during treatment with already validated clinical markers such as EGFR, KRAS and ALK. The cost of biomarker testing and the difficulty in obtaining enough metastatic NSCLC tissue are just two of the limitations for widespread pharmacogenetic testing in NSCLC. In the future, the use of readily accessible specimens such as blood for biomarker testing in NSCLC would greatly improve therapeutic prediction. Furthermore, the creation

of a complex biomarker array system based on a combination of several predictive markers would be beneficial given that combination therapies are more commonly used than monotherapies.

Additional research is required to clear the discrepancies and contradictory studies published involving the role of ABC transporters in NSCLC. ABC transporters appear beneficial not just as candidates for enhancement of intracellular drug retention, but they may be an emerging class of predictive and prognostic markers. Lack of effective clinical application of inhibitors of ABC transporters remains a big challenge despite efforts put into development of inhibitors. Given the dismal survival rate of this disease, all aspects that affect tumor response to chemotherapeutic agents need to be investigated to see how they can be harnessed to improve clinical responses.

## Acknowledgments

JWT is supported by NRSA Institutional Postdoctoral Training Grant (2T32-CA009035-36). Funding for EHB is provided by Tobacco Settlement Funds and CA06927 to Fox Chase Cancer Center.

## REFERENCES

- [1]. Jemal A, et al. Global cancer statistics. *CA Cancer J Clin.* 2011; 61(2):69–90. <http://dx.doi.org/10.3322/caac.20107>. [PubMed: 21296855]
- [2]. Siegel RD, Naishadham, Jemal A. Cancer statistics 2012. *CA Cancer J Clin.* 2012; 62(1):10–29. <http://dx.doi.org/10.3322/caac.20138>. [PubMed: 22237781]
- [3]. Vineis P, et al. Tobacco and cancer: recent epidemiological evidence. *J Natl Cancer Inst.* 2004; 96(2):99–106. <http://dx.doi.org/10.1093/jnci/djh014>. [PubMed: 14734699]
- [4]. Hang B. Formation and repair of tobacco carcinogen-derived bulky DNA adducts. *J Nucleic Acids.* 2010; 2010:709521. [PubMed: 21234336]
- [5]. Parkin DM. Tobacco-attributable cancer burden in the UK in 2010. *Br J Cancer.* 2011; 105(Suppl 2):S6–S13. <http://dx.doi.org/10.1038/bjc.2011.475>. [PubMed: 22158323]
- [6]. Takahashi H, et al. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. *Cancer Cell.* 2010; 17(1):89–97. <http://dx.doi.org/10.1016/j.ccr.2009.12.008>. [PubMed: 20129250]
- [7]. Burlakova EB, et al. Biomarkers of oxidative stress and smoking in cancer patients. *J Cancer Res Ther.* 2010; 6(1):47–53. <http://dx.doi.org/10.4103/0973-1482.63569>. [PubMed: 20479547]
- [8]. Hecht SS. Lung carcinogenesis by tobacco smoke. *Int J Cancer.* 2012; 131(12):2724–32. <http://dx.doi.org/10.1002/ijc.27816>. [PubMed: 22945513]
- [9]. Rosenberger A, et al. Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. *BMC Cancer.* 2008; 8:60. <http://dx.doi.org/10.1186/1471-2407-8-60>. [PubMed: 18298806]
- [10]. Broman K, et al. Aggregation of lung cancer in families: results from a population-based case-control study in Germany. *Am J Epidemiol.* 2000; 152(6):497–505. <http://dx.doi.org/10.1093/aje/152.6.497>. [PubMed: 10997539]
- [11]. Etzel CJ, Amos CI, Spitz MR. Risk for smoking-related cancer among relatives of lung cancer patients. *Cancer Res.* 2003; 63(23):8531–5. [PubMed: 14679021]
- [12]. Amos CI, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nat Genet.* 2008; 40(5):616–22. <http://dx.doi.org/10.1038/ng.109>. [PubMed: 18385676]
- [13]. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. *Lancet Oncol.* 2011; 12(4):399–408. [http://dx.doi.org/10.1016/S1470-2045\(10\)70126-1](http://dx.doi.org/10.1016/S1470-2045(10)70126-1). [PubMed: 20951091]
- [14]. American Cancer Society. *Cancer facts & figures.* Atlanta: 2013.

- [15]. Ettinger DS, et al. Non-small cell lung cancer. *J Natl Compr Canc Netw*. 2010; 8(7):740–801. [PubMed: 20679538]
- [16]. Cetin K, et al. Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. *Clin Epidemiol*. 2011; 3:139–48. [PubMed: 21607015]
- [17]. D'Arcangelo M, Cappuzzo F. K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. *ISRN Mol Biol*. 2012; 2012:8.
- [18]. Howlader, N., et al. SEER Cancer Statistics Review 1975-2009 (Vintage 2009 Populations). National Cancer Institute; Bethesda, MD: Apr. 2012 [http://seer.cancer.gov/csr/1975\\_2009\\_pops09/](http://seer.cancer.gov/csr/1975_2009_pops09/) based on November 2011 SEER data submission, posted to the SEER web site 2012
- [19]. Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer: a practical guide. *Am J Clin Pathol*. 2012; 138(3):332–46. <http://dx.doi.org/10.1309/AJCPFR12WJKCEEZZ>. [PubMed: 22912349]
- [20]. Travis WD, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol*. 2011; 6(2):244–85. <http://dx.doi.org/10.1097/JTO.0b013e318206a221>. [PubMed: 21252716]
- [21]. Crino L, et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010; 21(Suppl 5):v103–15. <http://dx.doi.org/10.1093/annonc/mdq207>. [PubMed: 20555058]
- [22]. Goldstraw P, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol*. 2007; 2(8):706–14. <http://dx.doi.org/10.1097/JTO.0b013e31812f3c1a>. [PubMed: 17762336]
- [23]. Chansky K, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. *J Thorac Oncol*. 2009; 4(7):792–801. <http://dx.doi.org/10.1097/JTO.0b013e3181a7716e>. [PubMed: 19458556]
- [24]. Winton T, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. *N Engl J Med*. 2005; 352(25):2589–97. <http://dx.doi.org/10.1056/NEJMoa043623>. [PubMed: 15972865]
- [25]. Kelsey CR, Clough RW, Marks LB. Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. *Cancer J*. 2006; 12(4):283–8. <http://dx.doi.org/10.1097/00130404-200607000-00006>. [PubMed: 16925972]
- [26]. Pfister DG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. *J Clin Oncol*. 2004; 22(2):330–53. <http://dx.doi.org/10.1200/JCO.2004.09.053>. [PubMed: 14691125]
- [27]. Xu Y, et al. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. *Lung Cancer*. 2011; 72(3):327–32. <http://dx.doi.org/10.1016/j.lungcan.2010.09.012>. [PubMed: 21056507]
- [28]. Azzoli CG, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. *J Clin Oncol*. 2009; 27(36):6251–66. <http://dx.doi.org/10.1200/JCO.2009.23.5622>. [PubMed: 19917871]
- [29]. Goffin J, et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. *J Thorac Oncol*. 2010; 5(2):260–74. <http://dx.doi.org/10.1097/JTO.0b013e3181c6f035>. [PubMed: 20101151]
- [30]. Schnabel PA, et al. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME). *Lung Cancer*. 2012; 78(3):263–9. <http://dx.doi.org/10.1016/j.lungcan.2012.09.001>. [PubMed: 23040326]
- [31]. Ohe Y, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell



- lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol.* 2007; 18(2):317–23. <http://dx.doi.org/10.1093/annonc/mdl377>. [PubMed: 17079694]
- [32]. Ma PC. Personalized targeted therapy in advanced non-small cell lung cancer. *Cleve Clin J Med.* 2012; 79(Electronic Suppl 1):eS56–60. [PubMed: 22614968]
- [33]. Mitsudomi T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncol.* 2010; 11(2):121–8. [http://dx.doi.org/10.1016/S1470-2045\(09\)70364-X](http://dx.doi.org/10.1016/S1470-2045(09)70364-X). [PubMed: 20022809]
- [34]. Fukuoka M, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J Clin Oncol.* 2011; 29(21):2866–74. <http://dx.doi.org/10.1200/JCO.2010.33.4235>. [PubMed: 21670455]
- [35]. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2004; 350(21):2129–39. <http://dx.doi.org/10.1056/NEJMoa040938>. [PubMed: 15118073]
- [36]. Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature.* 2007; 448(7153):561–6. <http://dx.doi.org/10.1038/nature05945>. [PubMed: 17625570]
- [37]. Riely GJ, Ladanyi M. KRAS mutations: an old oncogene becomes a new predictive biomarker. *J Mol Diagn.* 2008; 10(6):493–5. <http://dx.doi.org/10.2353/jmoldx.2008.080105>. [PubMed: 18832458]
- [38]. Rekhtman N, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. *Clin Cancer Res.* 2012; 18(4):1167–76. <http://dx.doi.org/10.1158/1078-0432.CCR-11-2109>. [PubMed: 22228640]
- [39]. Lippert TH, Ruoff HJ, Volm M. Current status of methods to assess cancer drug resistance. *Int J Med Sci.* 2011; 8(3):245–53. <http://dx.doi.org/10.7150/ijms.8.245>. [PubMed: 21487568]
- [40]. Gottesman MM. Mechanisms of cancer drug resistance. *Annu Rev Med.* 2002; 53:615–27. <http://dx.doi.org/10.1146/annurev.med.53.082901.103929>. [PubMed: 11818492]
- [41]. Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. *Pharmacology.* 2008; 81(4):275–300. <http://dx.doi.org/10.1159/000115967>. [PubMed: 18259091]
- [42]. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. *Nat Rev Cancer.* 2005; 5(5):341–54. <http://dx.doi.org/10.1038/nrc1609>. [PubMed: 15864276]
- [43]. Baselga J, Albanell J. Targeting epidermal growth factor receptor in lung cancer. *Curr Oncol Rep.* 2002; 4(4):317–24. <http://dx.doi.org/10.1007/s11912-002-0007-1>. [PubMed: 12044241]
- [44]. Chen G, et al. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. *BMC Med.* 2012; 10:28. <http://dx.doi.org/10.1186/1741-7015-10-28>. [PubMed: 22436374]
- [45]. Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. *Lancet Oncol.* 2003; 4(7):397–406. [http://dx.doi.org/10.1016/S1470-2045\(03\)01137-9](http://dx.doi.org/10.1016/S1470-2045(03)01137-9). [PubMed: 12850190]
- [46]. Jorissen RN, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. *Exp Cell Res.* 2003; 284(1):31–53. [http://dx.doi.org/10.1016/S0014-4827\(02\)00098-8](http://dx.doi.org/10.1016/S0014-4827(02)00098-8). [PubMed: 12648464]
- [47]. Sibilio M, et al. The epidermal growth factor receptor: from development to tumorigenesis. *Differentiation.* 2007; 75(9):770–87. <http://dx.doi.org/10.1111/j.1432-0436.2007.00238.x>. [PubMed: 17999740]
- [48]. Uberall I, et al. The status and role of ErbB receptors in human cancer. *Exp Mol Pathol.* 2008; 84(2):79–89. <http://dx.doi.org/10.1016/j.yexmp.2007.12.002>. [PubMed: 18279851]
- [49]. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. *Nat Rev Cancer.* 2012; 12(8):553–63. <http://dx.doi.org/10.1038/nrc3309>. [PubMed: 22785351]

- [50]. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. *Cancer*. 2002; 94(5):1593–11. <http://dx.doi.org/10.1002/cncr.10372>. [PubMed: 11920518]
- [51]. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. *Pharmacol Ther*. 2004; 102(1):37–46. <http://dx.doi.org/10.1016/j.pharmthera.2004.01.002>. [PubMed: 15056497]
- [52]. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. *Oncogene*. 2009; 28(Suppl 1):S32–7. <http://dx.doi.org/10.1038/onc.2009.199>. [PubMed: 19680294]
- [53]. Sequist LV, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. *J Clin Oncol*. 2007; 25(5):587–95. <http://dx.doi.org/10.1200/JCO.2006.07.3585>. [PubMed: 17290067]
- [54]. Sharma SV, et al. Epidermal growth factor receptor mutations in lung cancer. *Nat Rev Cancer*. 2007; 7(3):169–81. <http://dx.doi.org/10.1038/nrc2088>. [PubMed: 17318210]
- [55]. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. *Clin Cancer Res*. 2006; 12(24):7242–51. <http://dx.doi.org/10.1158/1078-0432.CCR-06-0646>. [PubMed: 17189395]
- [56]. Pirker R, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. *Lancet Oncol*. 2012; 13(1):33–42. [http://dx.doi.org/10.1016/S1470-2045\(11\)70318-7](http://dx.doi.org/10.1016/S1470-2045(11)70318-7). [PubMed: 22056021]
- [57]. Milas I, et al. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases. *Clin Cancer Res*. 2003; 9(3):1070–6. [PubMed: 12631609]
- [58]. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. *Clin Lung Cancer*. 2004; 6(Suppl 1):S20–3. <http://dx.doi.org/10.3816/CLC.2004.s.010>. [PubMed: 15638953]
- [59]. Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med*. 2005; 353(2):123–32. <http://dx.doi.org/10.1056/NEJMoa050753>. [PubMed: 16014882]
- [60]. Chang A, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. *J Thorac Oncol*. 2006; 1(8):847–55. <http://dx.doi.org/10.1097/01243894-200610000-00014>. [PubMed: 17409969]
- [61]. Rosell R, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. *Ann Oncol*. 2008; 19(2):362–9. <http://dx.doi.org/10.1093/annonc/mdm474>. [PubMed: 17947225]
- [62]. Jackman DM, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. *Clin Cancer Res*. 2009; 15(16):5267–73. <http://dx.doi.org/10.1158/1078-0432.CCR-09-0888>. [PubMed: 19671843]
- [63]. Lin L, Bivona T. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. *Chemother Res Pract*. 2012; 2012:817297. [PubMed: 22970367]
- [64]. Bell DW, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. *Nat Genet*. 2005; 37(12):1315–6. <http://dx.doi.org/10.1038/ng1671>. [PubMed: 16258541]
- [65]. Pao W, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med*. 2005; 2(3):e73. <http://dx.doi.org/10.1371/journal.pmed.0020073>. [PubMed: 15737014]
- [66]. Kobayashi S, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. *N Engl J Med*. 2005; 352(8):786–92. <http://dx.doi.org/10.1056/NEJMoa044238>. [PubMed: 15728811]

- [67]. Sos ML, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. *Cancer Res.* 2009; 69(8):3256–61. <http://dx.doi.org/10.1158/0008-5472.CAN-08-4055>. [PubMed: 19351834]
- [68]. She QB, et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. *Cancer Cell.* 2005; 8(4):287–97. <http://dx.doi.org/10.1016/j.ccr.2005.09.006>. [PubMed: 16226704]
- [69]. Vivanco I, et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. *Proc Natl Acad Sci USA.* 2010; 107(14):6459–64. <http://dx.doi.org/10.1073/pnas.0911188107>. [PubMed: 20308550]
- [70]. Yamamoto H, et al. PIK3CA mutations and copy number gains in human lung cancers. *Cancer Res.* 2008; 68(17):6913–21. <http://dx.doi.org/10.1158/0008-5472.CAN-07-5084>. [PubMed: 18757405]
- [71]. Ludovini V, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. *Ann Oncol.* 2009; 20(5):842–9. <http://dx.doi.org/10.1093/annonc/mdn727>. [PubMed: 19153117]
- [72]. Cortot AB, et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. *Cancer Res.* 2013; 73(2):834–43. <http://dx.doi.org/10.1158/0008-5472.CAN-12-2066>. [PubMed: 23172312]
- [73]. Sharma SV, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell.* 2010; 141(1):69–80. <http://dx.doi.org/10.1016/j.cell.2010.02.027>. [PubMed: 20371346]
- [74]. Boch C, et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. *BMJ Open.* 2013; 3(4)
- [75]. Brugger W, et al. Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol.* 2011 <http://dx.doi.org/10.1200/JCO.2010.31.8162>.
- [76]. Eberhard DA, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol.* 2005; 23(25):5900–9. <http://dx.doi.org/10.1200/JCO.2005.02.857>. [PubMed: 16043828]
- [77]. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. *Proc Am Thorac Soc.* 2009; 6(2):201–5. <http://dx.doi.org/10.1513/pats.200809-107LC>. [PubMed: 19349489]
- [78]. Heinemann V, et al. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. *Cancer Treat Rev.* 2009; 35(3): 262–71. <http://dx.doi.org/10.1016/j.ctrv.2008.11.005>. [PubMed: 19117687]
- [79]. Rodenhuis S, et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. *N Engl J Med.* 1987; 317(15):929–35. <http://dx.doi.org/10.1056/NEJM198710083171504>. [PubMed: 3041218]
- [80]. Westra WH, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. *Cancer.* 1993; 72(2):432–8. [http://dx.doi.org/10.1002/1097-0142\(19930715\)72:2<432::AID-CNCR2820720219>3.0.CO;2-](http://dx.doi.org/10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-) [PubMed: 8319174]
- [81]. Bos JL. RAS oncogenes in human cancer: a review. *Cancer Res.* 1989; 49(17):4682–9. [PubMed: 2547513]
- [82]. Riely GJ, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. *Clin Cancer Res.* 2008; 14(18):5731–4. <http://dx.doi.org/10.1158/1078-0432.CCR-08-0646>. [PubMed: 18794081]
- [83]. Ahrendt SA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. *Cancer.* 2001; 92(6):1525–30. [http://dx.doi.org/10.1002/1097-0142\(20010915\)92:6<1525::AID-CNCR1478>3.0.CO;2-H](http://dx.doi.org/10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H). [PubMed: 11745231]

- [84]. Pao W, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. *PLoS Med.* 2005; 2(1):e17. <http://dx.doi.org/10.1371/journal.pmed.0020017>. [PubMed: 15696205]
- [85]. Garcia J, et al. KRAS mutational testing in the selection of patients for EGFR-targeted therapies. *Semin Diagn Pathol.* 2008; 25(4):288–94. <http://dx.doi.org/10.1053/j.semdp.2008.08.003>. [PubMed: 19013894]
- [86]. Mascaux C, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. *Br J Cancer.* 2005; 92(1):131–9. <http://dx.doi.org/10.1038/sj.bjc.6602258>. [PubMed: 15597105]
- [87]. Zhu CQ, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. *J Clin Oncol.* 2008; 26(26):4268–75. <http://dx.doi.org/10.1200/JCO.2007.14.8924>. [PubMed: 18626007]
- [88]. van Zandwijk N, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. *Ann Oncol.* 2007; 18(1):99–103. <http://dx.doi.org/10.1093/annonc/mdl323>. [PubMed: 17060486]
- [89]. Douillard JY, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. *J Clin Oncol.* 2010; 28(5):744–52. <http://dx.doi.org/10.1200/JCO.2009.24.3030>. [PubMed: 20038723]
- [90]. Janne PA, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. *Lancet Oncol.* 2013; 14(1):38–47. [http://dx.doi.org/10.1016/S1470-2045\(12\)70489-8](http://dx.doi.org/10.1016/S1470-2045(12)70489-8). [PubMed: 23200175]
- [91]. Heuckmann JM, Rauh D, Thomas RK. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. *J Clin Oncol.* 2012; 30(27):3417–20. <http://dx.doi.org/10.1200/JCO.2012.43.1825>. [PubMed: 22915655]
- [92]. Riely GJ, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. *Clin Cancer Res.* 2007; 13(17):5150–5. <http://dx.doi.org/10.1158/1078-0432.CCR-07-0560>. [PubMed: 17785570]
- [93]. Yun CH, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc Natl Acad Sci USA.* 2008; 105(6):2070–5. <http://dx.doi.org/10.1073/pnas.0709662105>. [PubMed: 18227510]
- [94]. Yun CH, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. *Cancer Cell.* 2007; 11(3):217–27. <http://dx.doi.org/10.1016/j.ccr.2006.12.017>. [PubMed: 17349580]
- [95]. Azam M, et al. Activation of tyrosine kinases by mutation of the gatekeeper threonine. *Nat Struct Mol Biol.* 2008; 15(10):1109–18. <http://dx.doi.org/10.1038/nsmb.1486>. [PubMed: 18794843]
- [96]. Carter TA, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. *Proc Natl Acad Sci USA.* 2005; 102(31):11011–6. <http://dx.doi.org/10.1073/pnas.0504952102>. [PubMed: 16046538]
- [97]. Balak MN, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. *Clin Cancer Res.* 2006; 12(21):6494–501. <http://dx.doi.org/10.1158/1078-0432.CCR-06-1570>. [PubMed: 17085664]
- [98]. Costa DB, et al. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. *J Clin Oncol.* 2008; 26(7):1182–4. author reply 1184–6. <http://dx.doi.org/10.1200/JCO.2007.14.9039>. [PubMed: 18309959]
- [99]. Bean J, et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. *Clin Cancer Res.* 2008; 14(22):7519–25. <http://dx.doi.org/10.1158/1078-0432.CCR-08-0151>. [PubMed: 19010870]
- [100]. Leguay T, et al. D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients. *Leukemia.* 2005; 19(12):2332–3. author reply 2333–4. <http://dx.doi.org/10.1038/sj.leu.2403993>. [PubMed: 16281074]

- [101]. Kwak EL, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. *Proc Natl Acad Sci USA*. 2005; 102(21):7665–70. <http://dx.doi.org/10.1073/pnas.0502860102>. [PubMed: 15897464]
- [102]. Ramalingam SS, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. *J Clin Oncol*. 2012; 30(27):3337–44. <http://dx.doi.org/10.1200/JCO.2011.40.9433>. [PubMed: 22753918]
- [103]. Janne PA, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. *Clin Cancer Res*. 2011; 17(5):1131–9. <http://dx.doi.org/10.1158/1078-0432.CCR-10-1220>. [PubMed: 21220471]
- [104]. Li D, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. *Oncogene*. 2008; 27(34):4702–11. <http://dx.doi.org/10.1038/onc.2008.109>. [PubMed: 18408761]
- [105]. Miller VA, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. *Lancet Oncol*. 2012; 13(5):528–38. [http://dx.doi.org/10.1016/S1470-2045\(12\)70087-6](http://dx.doi.org/10.1016/S1470-2045(12)70087-6). [PubMed: 22452896]
- [106]. Yang JC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. *Lancet Oncol*. 2012; 13(5):539–48. [http://dx.doi.org/10.1016/S1470-2045\(12\)70086-4](http://dx.doi.org/10.1016/S1470-2045(12)70086-4). [PubMed: 22452895]
- [107]. Yeh HH, et al. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. *Proc Natl Acad Sci USA*. 2011; 108(4):1603–8. <http://dx.doi.org/10.1073/pnas.1010744108>. [PubMed: 21220318]
- [108]. Sequist LV, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. *J Clin Oncol*. 2010; 28(18):3076–83. <http://dx.doi.org/10.1200/JCO.2009.27.9414>. [PubMed: 20479403]
- [109]. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. *Curr Opin Cell Biol*. 2003; 15(6):740–6. <http://dx.doi.org/10.1016/j.ceb.2003.10.006>. [PubMed: 14644200]
- [110]. Xiao D, He J. Epithelial mesenchymal transition and lung cancer. *J Thorac Dis*. 2010; 2(3):154–9. [PubMed: 22263037]
- [111]. Byers LA, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. *Clin Cancer Res*. 2013; 19(1):279–90. <http://dx.doi.org/10.1158/1078-0432.CCR-12-1558>. [PubMed: 23091115]
- [112]. Suda K, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. *J Thorac Oncol*. 2011; 6(7):1152–61. <http://dx.doi.org/10.1097/JTO.0b013e318216ee52>. [PubMed: 21597390]
- [113]. Thomson S, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. *Cancer Res*. 2005; 65(20):9455–62. <http://dx.doi.org/10.1158/0008-5472.CAN-05-1058>. [PubMed: 16230409]
- [114]. Nurwidya F, et al. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. *Cancer Res Treat*. 2012; 44(3):151–6. <http://dx.doi.org/10.4143/crt.2012.44.3.151>. [PubMed: 23091440]
- [115]. Engelman JA, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*. 2007; 316(5827):1039–43. <http://dx.doi.org/10.1126/science.1141478>. [PubMed: 17463250]
- [116]. Lutterbach B, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. *Cancer Res*. 2007; 67(5):2081–8. <http://dx.doi.org/10.1158/0008-5472.CAN-06-3495>. [PubMed: 17332337]
- [117]. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. *J Clin Oncol*. 2013; 31(8):1089–96. <http://dx.doi.org/10.1200/JCO.2012.43.9422>. [PubMed: 23401458]

- [118]. Sgambato A, et al. The c-Met inhibitors: a new class of drugs in the battle against advanced non-small-cell lung cancer. *Curr Pharm Des.* 2012; 18(37):6155–68. <http://dx.doi.org/10.2174/138161212803582478>. [PubMed: 22873759]
- [119]. Rikova K, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell.* 2007; 131(6):1190–203. <http://dx.doi.org/10.1016/j.cell.2007.11.025>. [PubMed: 18083107]
- [120]. Houtman SH, et al. Echinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubules. *Neuroscience.* 2007; 144(4):1373–82. <http://dx.doi.org/10.1016/j.neuroscience.2006.11.015>. [PubMed: 17196341]
- [121]. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. *J Cell Physiol.* 2004; 199(3):330–58. <http://dx.doi.org/10.1002/jcp.10472>. [PubMed: 15095281]
- [122]. Morris SW, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. *Science.* 1994; 263(5151):1281–4. <http://dx.doi.org/10.1126/science.8122112>. [PubMed: 8122112]
- [123]. Choi YL, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. *Cancer Res.* 2008; 68(13):4971–6. <http://dx.doi.org/10.1158/0008-5472.CAN-07-6158>. [PubMed: 18593892]
- [124]. Kwak EL, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med.* 2010; 363(18):1693–703. <http://dx.doi.org/10.1056/NEJMoa1006448>. [PubMed: 20979469]
- [125]. Rodig SJ, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. *Clin Cancer Res.* 2009; 15(16):5216–23. <http://dx.doi.org/10.1158/1078-0432.CCR-09-0802>. [PubMed: 19671850]
- [126]. Koivunen JP, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. *Clin Cancer Res.* 2008; 14(13):4275–83. <http://dx.doi.org/10.1158/1078-0432.CCR-08-0168>. [PubMed: 18594010]
- [127]. Shaw AT, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. *J Clin Oncol.* 2009; 27(26):4247–53. <http://dx.doi.org/10.1200/JCO.2009.22.6993>. [PubMed: 19667264]
- [128]. McDermott U, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. *Cancer Res.* 2008; 68(9):3389–95. <http://dx.doi.org/10.1158/0008-5472.CAN-07-6186>. [PubMed: 18451166]
- [129]. Ou SH, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. *Oncologist.* 2012; 17(11):1351–75. <http://dx.doi.org/10.1634/theoncologist.2012-0311>. [PubMed: 22989574]
- [130]. Shaw AT, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol.* 2011; 12(11):1004–12. [http://dx.doi.org/10.1016/S1470-2045\(11\)70232-7](http://dx.doi.org/10.1016/S1470-2045(11)70232-7). [PubMed: 21933749]
- [131]. Choi YL, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med.* 2010; 363(18):1734–9. <http://dx.doi.org/10.1056/NEJMoa1007478>. [PubMed: 20979473]
- [132]. Katayama R, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci USA.* 2011; 108(18):7535–40. <http://dx.doi.org/10.1073/pnas.1019559108>. [PubMed: 21502504]
- [133]. Lu L, et al. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. *Biochemistry.* 2009; 48(16):3600–9. <http://dx.doi.org/10.1021/bi8020923>. [PubMed: 19249873]
- [134]. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. *Blood.* 2005; 105(7):2640–53. <http://dx.doi.org/10.1182/blood-2004-08-3097>. [PubMed: 15618470]

- [135]. Linardou H, et al. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. *Nat Rev Clin Oncol*. 2009; 6(6):352–66. <http://dx.doi.org/10.1038/nrclinonc.2009.62>. [PubMed: 19483740]
- [136]. Katayama R, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. *Sci Transl Med*. 2012; 4(120):120ra17.
- [137]. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. *J Clin Oncol*. 2013; 31(8):1105–11. <http://dx.doi.org/10.1200/JCO.2012.44.5353>. [PubMed: 23401436]
- [138]. Kim S, et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. *J Thorac Oncol*. 2013; 8(4):415–22. <http://dx.doi.org/10.1097/JTO.0b013e318283dcc0>. [PubMed: 23344087]
- [139]. Doebele RC, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res*. 2012; 18(5):1472–82. <http://dx.doi.org/10.1158/1078-0432.CCR-11-2906>. [PubMed: 22235099]
- [140]. Hong DS, et al. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. *Cancer Treat Rev*. 2013; 39(4):375–87. <http://dx.doi.org/10.1016/j.ctrv.2012.10.001>. [PubMed: 23199899]
- [141]. Barrott JJ, Haystead TA. Hsp90, an unlikely ally in the war on cancer. *FEBS J*. 2013; 280(6): 1381–96. <http://dx.doi.org/10.1111/febs.12147>. [PubMed: 23356585]
- [142]. Sequist LV, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. *J Clin Oncol*. 2010; 28(33):4953–60. <http://dx.doi.org/10.1200/JCO.2010.30.8338>. [PubMed: 20940188]
- [143]. Normant E, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. *Oncogene*. 2011; 30(22):2581–6. <http://dx.doi.org/10.1038/onc.2010.625>. [PubMed: 21258415]
- [144]. Sang J, et al. Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. *Cancer Discov*. 2013; 3(4):430–43. <http://dx.doi.org/10.1158/2159-8290.CD-12-0440>. [PubMed: 23533265]
- [145]. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. *Adv Drug Deliv Rev*. 2003; 55(1):3–29. [http://dx.doi.org/10.1016/S0169-409X\(02\)00169-2](http://dx.doi.org/10.1016/S0169-409X(02)00169-2). [PubMed: 12535572]
- [146]. Choi YH, Yu AM. ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development. *Curr Pharm Des*. 2013
- [147]. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. *Annu Rev Biochem*. 1993; 62:385–27. <http://dx.doi.org/10.1146/annurev.bi.62.070193.002125>. [PubMed: 8102521]
- [148]. Goda K, Bacso Z, Szabo G. Multidrug resistance through the spectacle of P-glycoprotein. *Curr Cancer Drug Targets*. 2009; 9(3):281–97. <http://dx.doi.org/10.2174/156800909788166493>. [PubMed: 19442049]
- [149]. Amiri-Kordestani L, et al. Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies. *Drug Resist Updat*. 2012; 15(1-2): 50–61. <http://dx.doi.org/10.1016/j.drug.2012.02.002>. [PubMed: 22464282]
- [150]. Cole SP, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science*. 1992; 258(5088):1650–4. <http://dx.doi.org/10.1126/science.1360704>. [PubMed: 1360704]
- [151]. Doyle LA, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc Natl Acad Sci USA*. 1998; 95(26):15665–70. <http://dx.doi.org/10.1073/pnas.95.26.15665>. [PubMed: 9861027]
- [152]. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. *Biochim Biophys Acta*. 1976; 455(1):152–62. [http://dx.doi.org/10.1016/0005-2736\(76\)90160-7](http://dx.doi.org/10.1016/0005-2736(76)90160-7). [PubMed: 990323]
- [153]. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. *Pharmacogenomics*. 2008; 9(1):105–27. <http://dx.doi.org/10.2217/14622416.9.1.105>. [PubMed: 18154452]


- [154]. Szakacs G, et al. Targeting multidrug resistance in cancer. *Nat Rev Drug Discov.* 2006; 5(3): 219–34. <http://dx.doi.org/10.1038/nrd1984>. [PubMed: 16518375]
- [155]. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. *J Natl Cancer Inst.* 1997; 89(13):917–31. <http://dx.doi.org/10.1093/jnci/89.13.917>. [PubMed: 9214671]
- [156]. Shaffer BC, et al. Drug resistance: still a daunting challenge to the successful treatment of AML. *Drug Resist Updat.* 2012; 15(1-2):62–9. <http://dx.doi.org/10.1016/j.drug.2012.02.001>. [PubMed: 22409994]
- [157]. Wioland MA, et al. CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. *J Histochem Cytochem.* 2000; 48(9):1215–22. <http://dx.doi.org/10.1177/002215540004800905>. [PubMed: 10950878]
- [158]. Campbell L, et al. Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. *J Pharmacol Exp Ther.* 2003; 304(1): 441–52. <http://dx.doi.org/10.1124/jpet.102.042994>. [PubMed: 12490621]
- [159]. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. *Oncologist.* 2003; 8(5):411–24. <http://dx.doi.org/10.1634/theoncologist.8-5-411>. [PubMed: 14530494]
- [160]. Lai SL, et al. MDR1 gene expression in lung cancer. *J Natl Cancer Inst.* 1989; 81(15):1144–50. <http://dx.doi.org/10.1093/jnci/81.15.1144>. [PubMed: 2746668]
- [161]. Oka M, et al. The clinical role of MDR1 gene expression in human lung cancer. *Anticancer Res.* 1997; 17(1B):721–4. [PubMed: 9066608]
- [162]. Scagliotti GV, et al. Detection of multidrug resistance associated P-170 glycoprotein in previously untreated non small cell lung cancer. *Anticancer Res.* 1991; 11(6):2207–10. [PubMed: 1685647]
- [163]. Beer TW, Rowlands DC, Crocker J. Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours. *Thorax.* 1996; 51(5):526–9. <http://dx.doi.org/10.1136/thx.51.5.526>. [PubMed: 8711682]
- [164]. Merk J, et al. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? *Eur J Cardiothorac Surg.* 2011; 40(1):e29–33. <http://dx.doi.org/10.1016/j.ejcts.2011.02.010>. [PubMed: 21420313]
- [165]. Chiou JF, et al. Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. *Lung.* 2003; 181(5):267–73. <http://dx.doi.org/10.1007/s00408-003-1029-7>. [PubMed: 14705770]
- [166]. Abe Y, et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells *in vivo*. *Br J Cancer.* 1996; 74(12):1929–34. <http://dx.doi.org/10.1038/bjc.1996.655>. [PubMed: 8980392]
- [167]. Yeh JJ, et al. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. *Respiration.* 2003; 70(1):32–5. <http://dx.doi.org/10.1159/000068411>. [PubMed: 12584388]
- [168]. Mahon FX, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. *Blood.* 2000; 96(3):1070–9. [PubMed: 10910924]
- [169]. Assef Y, et al. Imatinib resistance in multidrug-resistant K562 human leukemic cells. *Leuk Res.* 2009; 33(5):710–6. <http://dx.doi.org/10.1016/j.leukres.2008.09.024>. [PubMed: 18977528]
- [170]. Hegedus T, et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. *Biochim Biophys Acta.* 2002; 1587(2-3):318–25. [http://dx.doi.org/10.1016/S0925-4439\(02\)00095-9](http://dx.doi.org/10.1016/S0925-4439(02)00095-9). [PubMed: 12084474]
- [171]. Haouala A, et al. siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors. *Drug Metab Lett.* 2010; 4(2): 114–119. <http://dx.doi.org/10.2174/187231210791292726>. [PubMed: 20446917]
- [172]. Marchetti S, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in *in vitro* and *in vivo* pharmacokinetic studies employing *Bcrp1<sup>-/-</sup>/Mdr1a/1b<sup>-/-</sup>* (triple-knockout) and wild-type mice. *Mol Cancer Ther.* 2008; 7(8):2280–7. <http://dx.doi.org/10.1158/1535-7163.MCT-07-2250>. [PubMed: 18723475]



- [173]. Dohse M, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. *Drug Metab Dispos.* 2010; 38(8):1371–80. <http://dx.doi.org/10.1124/dmd.109.031302>. [PubMed: 20423956]
- [174]. Davies A, et al. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. *Leukemia.* 2009; 23(11):1999–2006. <http://dx.doi.org/10.1038/leu.2009.166>. [PubMed: 19710702]
- [175]. Harmsen S, et al. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors. *Eur J Pharm Sci.* 2013; 48(4-5):644–9. <http://dx.doi.org/10.1016/j.ejps.2012.12.019>. [PubMed: 23277288]
- [176]. Kitazaki T, et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. *Lung Cancer.* 2005; 49(3):337–43. <http://dx.doi.org/10.1016/j.lungcan.2005.03.035>. [PubMed: 15955594]
- [177]. Shi Z, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. *Cancer Res.* 2007; 67(22):11012–20. <http://dx.doi.org/10.1158/0008-5472.CAN-07-2686>. [PubMed: 18006847]
- [178]. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. *Toxicol Appl Pharmacol.* 2005; 204(3):216–37. <http://dx.doi.org/10.1016/j.taap.2004.10.012>. [PubMed: 15845415]
- [179]. He SM, et al. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). *Curr Med Chem.* 2011; 18(3):439–81. <http://dx.doi.org/10.2174/092986711794839197>. [PubMed: 21143116]
- [180]. Van der Deen M, et al. Diminished expression of Multidrug Resistance-associated Protein 1 (MRP1) in bronchial epithelium of COPD patients. *Am J Respir Crit Care Med.* 2003; 167:A397.
- [181]. Sakamoto A, et al. Quantitative expression of human drug transporter proteins in lung tissues: Analysis of regional, gender, and interindividual differences by liquid chromatography-tandem mass spectrometry. *J Pharm Sci.* 2013 <http://dx.doi.org/10.1002/jps.23606>.
- [182]. Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. *Trends Pharmacol Sci.* 2006; 27(8):438–46. <http://dx.doi.org/10.1016/j.tips.2006.06.008>. [PubMed: 16820223]
- [183]. Borst P, et al. A family of drug transporters: the multidrug resistance-associated proteins. *J Natl Cancer Inst.* 2000; 92(16):1295–302. <http://dx.doi.org/10.1093/jnci/92.16.1295>. [PubMed: 10944550]
- [184]. Ota E, et al. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. *Br J Cancer.* 1995; 72(3):550–4. <http://dx.doi.org/10.1038/bjc.1995.372>. [PubMed: 7669560]
- [185]. Sugawara I, et al. Preferential expression of the multidrug-resistance-associated protein (MRP) in adenocarcinoma of the lung. *Int J Cancer.* 1995; 64(5):322–5. <http://dx.doi.org/10.1002/ijc.2910640507>. [PubMed: 7591304]
- [186]. Doubre H, et al. Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). *Int J Cancer.* 2005; 113(4):568–74. <http://dx.doi.org/10.1002/ijc.20617>. [PubMed: 15472893]
- [187]. Li J, et al. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival. *Clin Lung Cancer.* 2009; 10(6): 414–21. <http://dx.doi.org/10.3816/CLC.2009.n.078>. [PubMed: 19900859]
- [188]. Li XQ, et al. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. *Int J Biol Markers.* 2009; 24(4):230–7. [PubMed: 20082278]
- [189]. Leslie EM, et al. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. *Mol Pharmacol.* 2001; 59(5):1171–80. [PubMed: 11306701]
- [190]. Rungsardthong K, Mares-Samano S, Penny J. Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer. *Bioinformation.* 2012; 8(19):907–11. <http://dx.doi.org/10.6026/97320630008907>. [PubMed: 23144549]

- [191]. Hopper E, et al. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. *Cancer Lett.* 2001; 162(2):181–91. [http://dx.doi.org/10.1016/S0304-3835\(00\)00646-7](http://dx.doi.org/10.1016/S0304-3835(00)00646-7). [PubMed: 11146224]
- [192]. Takayanagi S, et al. Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. *J Exp Ther Oncol.* 2004; 4(3):239–46. [PubMed: 15724843]
- [193]. Bleasby K, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. *Xenobiotica.* 2006; 36(10-11):963–88. <http://dx.doi.org/10.1080/00498250600861751>. [PubMed: 17118916]
- [194]. Hopper-Borge E, et al. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. *Cancer Res.* 2004; 64(14):4927–30. <http://dx.doi.org/10.1158/0008-5472.CAN-03-3111>. [PubMed: 15256465]
- [195]. Hopper-Borge EA, et al. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. *Cancer Res.* 2009; 69(1):178–84. <http://dx.doi.org/10.1158/0008-5472.CAN-08-1420>. [PubMed: 19118001]
- [196]. Hopper-Borge EA, et al. Contribution of Abcc10 (Mrp7) to *in vivo* paclitaxel resistance as assessed in Abcc10(–/–) mice. *Cancer Res.* 2011; 71(10):3649–57. <http://dx.doi.org/10.1158/0008-5472.CAN-10-3623>. [PubMed: 21576088]
- [197]. Mohelnikova-Duchonova B, et al. Differences in Transcript Levels of ABC Transporters Between Pancreatic Adenocarcinoma and Nonneoplastic Tissues. *Pancreas.* 2013; 42(4):707–16. <http://dx.doi.org/10.1097/MPA.0b013e318279b861>. [PubMed: 23462326]
- [198]. Hlavata I, et al. The role of ABC transporters in progression and clinical outcome of colorectal cancer. *Mutagenesis.* 2012; 27(2):187–96. <http://dx.doi.org/10.1093/mutage/ger075>. [PubMed: 22294766]
- [199]. Wang P, et al. Expression and Clinical Significance of ABCC10 in the Patients with Non-small Cell Lung Cancer. *Chin J Lung Cancer.* 2009; 12(8):875–8.
- [200]. Oguri T, et al. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. *Mol Cancer Ther.* 2008; 7(5):1150–5. <http://dx.doi.org/10.1158/1535-7163.MCT-07-2088>. [PubMed: 18445659]
- [201]. Bessho Y, et al. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. *Oncol Rep.* 2009; 21(1):263–8. [PubMed: 19082471]
- [202]. Nakatomi K, et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. *Biochem Biophys Res Commun.* 2001; 288(4):827–32. <http://dx.doi.org/10.1006/bbrc.2001.5850>. [PubMed: 11688982]
- [203]. Kawabata S, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. *Biochem Biophys Res Commun.* 2001; 280(5):1216–23. <http://dx.doi.org/10.1006/bbrc.2001.4267>. [PubMed: 11162657]
- [204]. Yuan J, et al. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. *Cancer Chemother Pharmacol.* 2009; 63(6):1103–10. <http://dx.doi.org/10.1007/s00280-008-0838-z>. [PubMed: 18820913]
- [205]. Maliepaard M, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. *Cancer Res.* 2001; 61(8):3458–64. [PubMed: 11309308]
- [206]. Natarajan K, et al. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. *Biochem Pharmacol.* 2012; 83(8):1084–103. <http://dx.doi.org/10.1016/j.bcp.2012.01.002>. [PubMed: 22248732]
- [207]. Scheffer GL, et al. Multidrug resistance related molecules in human and murine lung. *J Clin Pathol.* 2002; 55(5):332–9. <http://dx.doi.org/10.1136/jcp.55.5.332>. [PubMed: 11986335]
- [208]. van der Deen M, et al. ATP-binding cassette (ABC) transporters in normal and pathological lung. *Respir Res.* 2005; 6:59. <http://dx.doi.org/10.1186/1465-9921-6-59>. [PubMed: 15967026]
- [209]. Kim YH, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. *Lung Cancer.* 2009; 65(1):105–11. <http://dx.doi.org/10.1016/j.lungcan.2008.10.008>. [PubMed: 19036469]

- [210]. Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. *Drug Resist Updat*. 2012; 15(1-2):70–80. <http://dx.doi.org/10.1016/j.drug.2012.01.005>. [PubMed: 22325423]
- [211]. Nakamura Y, et al. Gefitinib (“Iressa”, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. *Cancer Res*. 2005; 65(4):1541–6. <http://dx.doi.org/10.1158/0008-5472.CAN-03-2417>. [PubMed: 15735043]
- [212]. Usuda J, et al. Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a “never-smoked” female patient with advanced non-small cell lung cancer. *Lung Cancer*. 2007; 58(2):296–9. <http://dx.doi.org/10.1016/j.lungcan.2007.05.019>. [PubMed: 17618705]
- [213]. Huang WC, et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. *J Biol Chem*. 2011; 286(23):20558–68. <http://dx.doi.org/10.1074/jbc.M111.240796>. [PubMed: 21487020]
- [214]. Shi Z, et al. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. *Oncol Rep*. 2009; 21(2):483–9. [PubMed: 19148526]
- [215]. Zhou Y, et al. Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. *Biochem Pharmacol*. 2009; 77(6):993–1001. <http://dx.doi.org/10.1016/j.bcp.2008.12.005>. [PubMed: 19150344]
- [216]. Sun YL, et al. Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. *PLoS One*. 2013; 8(2):e55576. <http://dx.doi.org/10.1371/journal.pone.0055576>. [PubMed: 23393594]
- [217]. Tiwari AK, et al. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. *Cancer Lett*. 2012
- [218]. Kuang YH, et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. *Biochem Pharmacol*. 2010; 79(2):154–61. <http://dx.doi.org/10.1016/j.bcp.2009.08.021>. [PubMed: 19720054]



**Figure 1. A simplified illustration of mechanisms of resistance to conventional therapeutics and TKIs in NSCLC**

Response to TKIs targeting epidermal growth factor receptor (EGFR) can be affected by mechanisms that include the development of drug insensitive secondary mutations (T790M) in the kinase domain of the receptor; crosstalk with insulin-like Growth Factor Receptor 1 (IGFR-1); cross talk of amplified *MET* with epidermal growth factor receptor 3 (ERBB3) and mutations in *KRAS*. These mechanisms result in activation of signaling effectors such as STAT3, ERK1/2 and PI3K/AKT which support the proliferation and survival of drug resistant cells. ABC transporters such as ABCG2 and ABCB1 have been shown to efflux both TKIs and conventional therapeutics. The resulting decrease in intracellular drug concentrations is a factor in drug resistance. Targeting the oncogenic fusion protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) with TKIs such as crizotinib has also been shown to be negatively affected by the development of secondary gate keeper residue mutations such as L1196M, and the emergence of fusion negative tumors that render the disease insensitive to the drug. EGF (epidermal growth factor), IGF (insulin-like growth factor, HGF (hepatocyte growth factor), GTP (guanosine triphosphate).